IL270676B2 - A pharmaceutical combination comprising a polyunsaturated fatty acid and a chemotherapeutic agent for the treatment of a cancer - Google Patents

A pharmaceutical combination comprising a polyunsaturated fatty acid and a chemotherapeutic agent for the treatment of a cancer

Info

Publication number
IL270676B2
IL270676B2 IL270676A IL27067619A IL270676B2 IL 270676 B2 IL270676 B2 IL 270676B2 IL 270676 A IL270676 A IL 270676A IL 27067619 A IL27067619 A IL 27067619A IL 270676 B2 IL270676 B2 IL 270676B2
Authority
IL
Israel
Prior art keywords
cancer
compound
paclitaxel
pharmaceutical combination
carboplatin
Prior art date
Application number
IL270676A
Other languages
English (en)
Hebrew (he)
Other versions
IL270676B1 (en
IL270676A (https=
Original Assignee
Ability Pharmaceuticals S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ability Pharmaceuticals S L filed Critical Ability Pharmaceuticals S L
Publication of IL270676A publication Critical patent/IL270676A/en
Publication of IL270676B1 publication Critical patent/IL270676B1/en
Publication of IL270676B2 publication Critical patent/IL270676B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL270676A 2017-05-16 2018-05-15 A pharmaceutical combination comprising a polyunsaturated fatty acid and a chemotherapeutic agent for the treatment of a cancer IL270676B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382282 2017-05-16
PCT/EP2018/062554 WO2018210830A1 (en) 2017-05-16 2018-05-15 A pharmaceutical combination for the treatment of a cancer

Publications (3)

Publication Number Publication Date
IL270676A IL270676A (https=) 2020-01-30
IL270676B1 IL270676B1 (en) 2024-07-01
IL270676B2 true IL270676B2 (en) 2024-11-01

Family

ID=58765794

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270676A IL270676B2 (en) 2017-05-16 2018-05-15 A pharmaceutical combination comprising a polyunsaturated fatty acid and a chemotherapeutic agent for the treatment of a cancer

Country Status (16)

Country Link
US (3) US11260042B2 (https=)
EP (2) EP4234035A3 (https=)
JP (1) JP7208650B2 (https=)
KR (1) KR102569052B1 (https=)
CN (2) CN110636842A (https=)
AU (1) AU2018269462B2 (https=)
BR (1) BR112019023944A2 (https=)
CA (1) CA3063625A1 (https=)
CL (1) CL2019003288A1 (https=)
ES (1) ES2955524T3 (https=)
HU (1) HUE063275T2 (https=)
IL (1) IL270676B2 (https=)
MX (1) MX2019013683A (https=)
PL (1) PL3624786T3 (https=)
WO (1) WO2018210830A1 (https=)
ZA (1) ZA201907286B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102569052B1 (ko) * 2017-05-16 2023-08-22 어빌리티 파마슈티컬스 에스.엘. 암의 치료를 위한 약제학적 조합물
WO2021160650A1 (en) * 2020-02-10 2021-08-19 Ability Pharmaceuticals S.L. A pharmaceutical combination for the treatment of a cancer
CN120733048A (zh) * 2025-08-29 2025-10-03 天津医科大学总医院 一种用于治疗肺鳞癌的药物组合物及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63258816A (ja) * 1987-04-16 1988-10-26 Nippon Oil & Fats Co Ltd 抗癌剤組成物
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
GB9618420D0 (en) * 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
AU5928599A (en) * 1999-09-09 2001-04-10 Efa Sciences Llc. Methods for treating cell proliferative disorders including cancer
GB0011903D0 (en) 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
RU2284818C2 (ru) 2001-05-10 2006-10-10 Анормед, Инк. Комбинированная химиотерапия
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
SG175401A1 (en) 2009-05-08 2011-12-29 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
ES2601891T3 (es) 2011-10-18 2017-02-16 Nestec S.A. Composición para su uso en crecimiento cerebral y/o desarrollo cognitivo y/o psicomotor
UA114615C2 (uk) 2012-01-06 2017-07-10 Омтера Фармасьютікалз, Інк. Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти
KR102569052B1 (ko) * 2017-05-16 2023-08-22 어빌리티 파마슈티컬스 에스.엘. 암의 치료를 위한 약제학적 조합물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ABILITY PHARMA, ABILITY PHARMACEUTICALS ANNOUNCES FDA-ORPHAN DRUG DESIGNATION FOR ABTL0812 IN PANCREATIC CANCER, 14 December 2016 (2016-12-14) *

Also Published As

Publication number Publication date
EP4234035A3 (en) 2023-11-15
HUE063275T2 (hu) 2024-01-28
US11260042B2 (en) 2022-03-01
RU2019135507A3 (https=) 2021-09-03
EP3624786C0 (en) 2023-07-05
KR102569052B1 (ko) 2023-08-22
KR20200005573A (ko) 2020-01-15
US12280033B2 (en) 2025-04-22
CN119950727A (zh) 2025-05-09
RU2019135507A (ru) 2021-06-16
PL3624786T3 (pl) 2023-10-30
EP3624786A1 (en) 2020-03-25
ES2955524T3 (es) 2023-12-04
CA3063625A1 (en) 2018-11-22
US20210154166A1 (en) 2021-05-27
JP7208650B2 (ja) 2023-01-19
BR112019023944A2 (pt) 2020-06-09
US12053449B2 (en) 2024-08-06
WO2018210830A1 (en) 2018-11-22
EP3624786B1 (en) 2023-07-05
US20220257554A1 (en) 2022-08-18
CL2019003288A1 (es) 2020-05-08
AU2018269462B2 (en) 2024-04-18
EP4234035A2 (en) 2023-08-30
AU2018269462A1 (en) 2019-11-28
ZA201907286B (en) 2021-01-27
CN110636842A (zh) 2019-12-31
IL270676B1 (en) 2024-07-01
US20240350449A1 (en) 2024-10-24
IL270676A (https=) 2020-01-30
JP2020520385A (ja) 2020-07-09
MX2019013683A (es) 2020-01-15

Similar Documents

Publication Publication Date Title
Khalife et al. Thymoquinone from Nigella sativa seeds promotes the antitumor activity of noncytotoxic doses of topotecan in human colorectal cancer cells in vitro
Hsu et al. Fucoidan upregulates TLR4/CHOP-mediated caspase-3 and PARP activation to enhance cisplatin-induced cytotoxicity in human lung cancer cells
Sun et al. Scutellarin induces apoptosis and autophagy in NSCLC cells through ERK1/2 and AKT Signaling Pathways in vitro and in vivo
DK2799070T3 (en) EFFECTIVE AMPLIFIER FOR ANTITUMUM AGENTS
KR102182946B1 (ko) 메트포르민 및 디히드로쿠에르세틴을 포함하는 약학적 조합물 및 이의 암치료를 위한 용도
JP6666494B2 (ja) がんの処置のための医薬の組合せ
Zheng et al. Alkannin induces cytotoxic autophagy and apoptosis by promoting ROS-mediated mitochondrial dysfunction and activation of JNK pathway
Khalife et al. Antiproliferative and proapoptotic effects of topotecan in combination with thymoquinone on acute myelogenous leukemia
Tang et al. Combination of baicalein and 10-hydroxy camptothecin exerts remarkable synergetic anti-cancer effects
IL270676B1 (en) A pharmaceutical combination comprising a polyunsatured fatty acid and a chemotherapeutic agent for the treatment of a cancer
Wong et al. SRJ09, a promising anticancer drug lead: Elucidation of mechanisms of antiproliferative and apoptogenic effects and assessment of in vivo antitumor efficacy
Balsa et al. Cu (II)-acylhydrazone complex, a potent and selective antitumor agent against human osteosarcoma: Mechanism of action studies over in vitro and in vivo models
Lin et al. Shrimp anti-lipopolysaccharide factor peptide enhances the antitumor activity of cisplatin in vitro and inhibits HeLa cells growth in nude mice
KR20120116425A (ko) 작은 피리미딘 유도체 및 이의 사용 방법
KR102128866B1 (ko) 오로라 키나제 저해제를 사용하는 암 치료 방법
US20170136053A1 (en) Novel pharmaceutical composition and uses thereof
TWI430801B (zh) 使用小檗鹼化合物製造抑制癌幹細胞生長或轉移的藥劑之用途
Hu et al. The anti-osteosarcoma cell activity by a mTORC1/2 dual inhibitor RES-529
EP3043809B1 (en) Filipendula vulgaris extract and uses thereof
WO2015011732A2 (en) Plant poly-phenol and copper (ii) mediated degradation of dna and rna
Ren et al. Unleashing the Therapeutic Power of Natural Alkaloids in Triple‐Negative Breast Cancer: State‐of‐the‐Art Advances and Future Directions
ITRM20130312A1 (it) Estratto di cynara spp. e suoi usi.
CN102626412B (zh) 一种治疗恶性肿瘤的药物组合物
JP2023544251A (ja) 新規医薬化合物、その方法および使用
Fu et al. Natural Anti-Cancer Products